Clinical trials: Cystic Fibrosis - Complete
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups.
- Trial name
- NCT03251092
- Testing
- PTI-808, PTI-428, PTI-801
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
Cystic Fibrosis - Complete
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs.
- Trial name
- TMX (NCT07289035)
- Testing
- Tamoxifen Citrate 20Mg Tab
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Cystic Fibrosis (CF), Cystic Fibrosis - Complete
OnTrackCF: Engagement, Feasibility, and Acceptability Study
This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).
- Trial name
- OnTrackCF (NCT07031323)
- Testing
- OnTrackCF
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boston Children's Hospital
Long-term Safety of TIP
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401.
- Trial name
- NCT01775137
- Testing
- TBM100
- Where
- 21 sites in United States, Argentina and 7 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Infections, Pseudomonas Aeruginosa
Second Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were…
- Trial name
- NCT01069705
- Testing
- Tobramycin inhalation powder
- Where
- 17 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals